Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DYN5 | ISIN: CA23809L1085 | Ticker-Symbol: D4G
Tradegate
20.01.25
21:25 Uhr
0,004 Euro
-0,002
-33,33 %
Branche
Hardware
Aktienmarkt
Sonstige
1-Jahres-Chart
DATAMETREX AI LIMITED Chart 1 Jahr
5-Tage-Chart
DATAMETREX AI LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0040,00708:34
0,0040,00708:00
ACCESS Newswire
251 Leser
Artikel bewerten:
(1)

DataMetrex AI Ltd.: Datametrex Receives Approx $250K Purchase Order

Finanznachrichten News

TORONTO, ON / ACCESSWIRE / December 11, 2024 / Datametrex AI Limited (the "Company" or "Datametrex') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce that it has received purchase orders (P.O.) of approximately $250K CAD from its IT services on December 9, 2024. The estimated cost to deliver is approximately $188K, resulting in a gross profit margin of approximately 26%. This reflects the Company's strength and adaptability in a dynamic, competitive IT market, underscoring the effectiveness of its clear and strategic land and expansion strategy.

The success of the Company's AI & Tech division further highlights the Company's steady financial performance and strength in the partnership with its key clients in the various business sectors. Datametrex has demonstrated its commitment to delivering exceptional service and value to its clients.

Paul Haber, CEO of Datametrex, commented, "We are pleased to announce Datametrex's continued progress in the AI and Tech division. Through our strategic focus and strong partnership with major clients, we are confident in maintaining this positive momentum and deliver significant value to our shareholders and partners."

About Datametrex
Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, Healthcare, and Mobile Gaming. The Company excels in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology.

For more on Datametrex, please visit our Company website.

For Additional Information
Paul Haber, C.P.A., C.A., C.Dir
CEO & Chairman
info@datametrex.com
(416) 318-6501

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This news release contains "forward-looking statements," which involve risks, uncertainties, and factors that could cause actual results to differ materially from those anticipated. These statements are not historical facts and are generally identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," and similar expressions. Such statements include expectations related to game development and other Company plans.

While Datametrex believes the forward-looking information is reasonable as of the date of this release, these statements involve assumptions, risks, and uncertainties that could cause actual outcomes to differ. Key factors include general economic conditions, legislative and regulatory developments, access to capital, industry competition, and the Company's ability to execute its strategies. The Company does not undertake to update these statements, except as required by law. Readers are advised not to place undue reliance on forward-looking information.

Factors that could cause actual results to differ materially are detailed under "Risk Factors" in Datametrex's management's discussion and analysis and available on the Company's profile at www.sedarplus.ca.

This release does not constitute an offer to sell or a solicitation to buy, nor shall it constitute an offer, solicitation, or sale in any jurisdiction where such would be unlawful prior to registration or qualification under applicable securities laws. We seek Safe Harbor.

SOURCE: DataMetrex AI Ltd.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.